AMRX Valuation

Amneal Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

9.560

+0.01(0.105%)1D

Overview
Forecast
Valuation
Earnings

AMRX Relative Valuation

AMRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMRX is overvalued; if below, it's undervalued.

Historical Valuation

Amneal Pharmaceuticals Inc (AMRX) is now in the Overvalued zone, suggesting that its current forward PE ratio of 13.37 is considered Overvalued compared with the five-year average of 7.54. The fair price of Amneal Pharmaceuticals Inc (AMRX) is between 4.75 to 8.37 according to relative valuation methord. Compared to the current price of 9.56 USD , Amneal Pharmaceuticals Inc is Overvalued By 14.24%.

Relative Value

Fair Zone

4.75-8.37

Current Price：9.56

14.24%

Overvalued

13.37

Trailing

Forward

8.35

EV/EBITDA

Amneal Pharmaceuticals Inc. (AMRX) has a current EV/EBITDA of 8.35. The 5-year average EV/EBITDA is 6.74. The thresholds are as follows: Strongly Undervalued below 4.78, Undervalued between 4.78 and 5.76, Fairly Valued between 7.71 and 5.76, Overvalued between 7.71 and 8.69, and Strongly Overvalued above 8.69. The current Forward EV/EBITDA of 8.35 falls within the Overvalued range.

9.66

EV/EBIT

Amneal Pharmaceuticals Inc. (AMRX) has a current EV/EBIT of 9.66. The 5-year average EV/EBIT is 7.81. The thresholds are as follows: Strongly Undervalued below 5.83, Undervalued between 5.83 and 6.82, Fairly Valued between 8.81 and 6.82, Overvalued between 8.81 and 9.80, and Strongly Overvalued above 9.80. The current Forward EV/EBIT of 9.66 falls within the Overvalued range.

0.98

Amneal Pharmaceuticals Inc. (AMRX) has a current PS of 0.98. The 5-year average PS is 0.45. The thresholds are as follows: Strongly Undervalued below -0.10, Undervalued between -0.10 and 0.18, Fairly Valued between 0.73 and 0.18, Overvalued between 0.73 and 1.00, and Strongly Overvalued above 1.00. The current Forward PS of 0.98 falls within the Overvalued range.

8.48

P/OCF

Amneal Pharmaceuticals Inc. (AMRX) has a current P/OCF of 8.48. The 5-year average P/OCF is 3.86. The thresholds are as follows: Strongly Undervalued below -1.24, Undervalued between -1.24 and 1.31, Fairly Valued between 6.41 and 1.31, Overvalued between 6.41 and 8.95, and Strongly Overvalued above 8.95. The current Forward P/OCF of 8.48 falls within the Overvalued range.

12.01

P/FCF

Amneal Pharmaceuticals Inc. (AMRX) has a current P/FCF of 12.01. The 5-year average P/FCF is 4.06. The thresholds are as follows: Strongly Undervalued below -2.49, Undervalued between -2.49 and 0.79, Fairly Valued between 7.34 and 0.79, Overvalued between 7.34 and 10.61, and Strongly Overvalued above 10.61. The current Forward P/FCF of 12.01 falls within the Strongly Overvalued range.

Amneal Pharmaceuticals Inc (AMRX) has a current Price-to-Book (P/B) ratio of -26.78. Compared to its 3-year average P/B ratio of -5.98 , the current P/B ratio is approximately 347.58% higher. Relative to its 5-year average P/B ratio of -2.70, the current P/B ratio is about 890.08% higher. Amneal Pharmaceuticals Inc (AMRX) has a Forward Free Cash Flow (FCF) yield of approximately 9.02%. Compared to its 3-year average FCF yield of 14.00%, the current FCF yield is approximately -35.54% lower. Relative to its 5-year average FCF yield of 21.43% , the current FCF yield is about -57.91% lower.

-26.78

P/B

Median3y

-5.98

Median5y

-2.70

9.02

FCF Yield

Median3y

14.00

Median5y

21.43

Competitors Valuation Multiple

The average P/S ratio for AMRX's competitors is 26.09, providing a benchmark for relative valuation. Amneal Pharmaceuticals Inc Corp (AMRX) exhibits a P/S ratio of 0.98, which is -96.26% above the industry average. Given its robust revenue growth of 3.24%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AMRX.N

Amneal Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Viking Therapeutics Inc

Loss

3.04B

CRNX.O

Crinetics Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

4.04

13.24%

2.89B

Performance Decomposition

Market capitalization of AMRX increased by 14.90% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 2.39 to 4.92.

The secondary factor is the Revenue Growth, contributed 3.24%to the performance.

Overall, the performance of AMRX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

3.24%

701.78M → 724.51M

Revenue Growth

105.86%

2.39 → 4.92

Margin Expansion

-94.20%

15.19K → 881.19

P/E Change

14.90%